ATE145428T1
(de)
*
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
US6407221B1
(en)
|
1990-12-14 |
2002-06-18 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
US6004811A
(en)
*
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US5912170A
(en)
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US5843728A
(en)
*
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
CZ291754B6
(cs)
*
|
1993-07-16 |
2003-05-14 |
The General Hospital Corporation |
Proteinový chimerní receptor, terapeutická buňka, DNA kódující chimerní receptor a vektor
|
WO1995026985A1
(en)
*
|
1994-04-05 |
1995-10-12 |
Board Of Regents, The University Of Texas System |
Modified receptors that continuously signal
|
AU694222B2
(en)
|
1994-05-02 |
1998-07-16 |
Bernd Groner |
Bifunctional protein, preparation and use
|
US7354587B1
(en)
|
1994-07-06 |
2008-04-08 |
Immunomedics, Inc. |
Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
|
US5798100A
(en)
*
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
CN1142941C
(zh)
*
|
1994-08-02 |
2004-03-24 |
杰纳勒尔医疗公司 |
带cd4引诱物受体的细胞以及相关分子和方法
|
US5741899A
(en)
*
|
1995-02-02 |
1998-04-21 |
Cell Genesys, Inc. |
Chimeric receptors comprising janus kinase for regulating cellular pro liferation
|
US6103521A
(en)
*
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
EP0871495B1
(de)
*
|
1995-02-24 |
2005-06-15 |
The General Hospital Corporation |
Neuorientierung der zellulären immunität durch rezeptorchimären
|
US5916771A
(en)
*
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
US6420140B1
(en)
|
1996-10-11 |
2002-07-16 |
Abgenix, Inc. |
Production of multimeric protein by cell fusion method
|
CN1183968C
(zh)
*
|
1996-10-23 |
2005-01-12 |
宾夕法尼亚州立大学托管会 |
改良疫苗
|
CA2311574A1
(en)
|
1997-12-02 |
1999-06-10 |
Medarex, Inc. |
Cells expressing anti-fc receptor binding components
|
GB9809658D0
(en)
*
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
US7723111B2
(en)
|
2001-03-09 |
2010-05-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Activated dual specificity lymphocytes and their methods of use
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
US7901680B2
(en)
|
2005-10-19 |
2011-03-08 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) vaccines for cancer therapy
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
US8562988B2
(en)
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
US8435539B2
(en)
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
IL286053B2
(en)
|
2005-10-18 |
2023-03-01 |
Nat Jewish Health |
A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
|
KR20170078862A
(ko)
|
2008-05-16 |
2017-07-07 |
타이가 바이오테크놀로지스, 인코포레이티드 |
항체 및 그 제조 방법
|
EP3916010A1
(de)
|
2008-08-28 |
2021-12-01 |
Taiga Biotechnologies, Inc. |
Modulatoren von myc, verfahren zur verwendung davon und verfahren zur identifizierung von mitteln zur modulierung von myc
|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
UY33679A
(es)
|
2010-10-22 |
2012-03-30 |
Esbatech |
Anticuerpos estables y solubles
|
BR122021026169B1
(pt)
|
2010-12-09 |
2023-12-12 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula
|
US9833476B2
(en)
|
2011-08-31 |
2017-12-05 |
The Trustees Of Dartmouth College |
NKP30 receptor targeted therapeutics
|
WO2013169691A1
(en)
|
2012-05-07 |
2013-11-14 |
Trustees Of Dartmouth College |
Anti-b7-h6 antibody, fusion proteins, and methods of using the same
|
EP3868387A1
(de)
|
2012-07-20 |
2021-08-25 |
Taiga Biotechnologies, Inc. |
Verbesserte wiederherstellung und autorenkonstitution des hämatopoietischen abteils
|
WO2014031687A1
(en)
|
2012-08-20 |
2014-02-27 |
Jensen, Michael |
Method and compositions for cellular immunotherapy
|
RU2019137208A
(ru)
|
2013-02-20 |
2020-02-19 |
Новартис Аг |
ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
|
ES2814962T3
(es)
|
2013-02-20 |
2021-03-29 |
Novartis Ag |
Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
|
US10272115B2
(en)
|
2013-03-11 |
2019-04-30 |
Taiga Biotechnologies, Inc. |
Production and use of red blood cells
|
EP3623380A1
(de)
|
2013-03-15 |
2020-03-18 |
Michael C. Milone |
Targeting von zytotoxischen zellen mit chimären rezeptoren zur adoptiven immuntherapie
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
RU2714902C2
(ru)
|
2013-12-19 |
2020-02-20 |
Новартис Аг |
Химерные рецепторы антигена против мезотелина человека и их применение
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
CN106456724A
(zh)
|
2013-12-20 |
2017-02-22 |
博德研究所 |
使用新抗原疫苗的联合疗法
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
KR20240042250A
(ko)
|
2014-04-07 |
2024-04-01 |
노파르티스 아게 |
항-cd19 키메라 항원 수용체를 사용한 암의 치료
|
MX2017001011A
(es)
|
2014-07-21 |
2018-05-28 |
Novartis Ag |
Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
RU2741120C2
(ru)
|
2014-07-21 |
2021-01-22 |
Новартис Аг |
Лечение рака с использованием химерного антигенного рецептора cll-1
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
JP6815992B2
(ja)
|
2014-10-08 |
2021-01-20 |
ノバルティス アーゲー |
キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
|
CA2968987C
(en)
*
|
2014-12-08 |
2022-05-10 |
1Globe Biomedical Co., Ltd. |
Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
|
EP3234130B1
(de)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Verfahren zum profiling vom t-zell-rezeptor-repertoire
|
EP3234193B1
(de)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molekulare biomarker für krebsimmuntherapie
|
IL303247A
(en)
|
2014-12-29 |
2023-07-01 |
Novartis Ag |
Methods for preparing cells expressing a chimeric receptor antigen
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
US11896614B2
(en)
|
2015-04-17 |
2024-02-13 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
TWI806815B
(zh)
|
2015-05-20 |
2023-07-01 |
美商博德研究所有限公司 |
共有之gata3相關之腫瘤特異性新抗原
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
US11059880B2
(en)
|
2015-06-30 |
2021-07-13 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
|
WO2017015427A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
CN109069597A
(zh)
|
2015-12-22 |
2018-12-21 |
诺华股份有限公司 |
间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
CN117866991A
(zh)
|
2016-10-07 |
2024-04-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
GB201618106D0
(en)
|
2016-10-26 |
2016-12-07 |
Lift Biosciences Ltd |
Cancer-killing cells
|
CN113786476A
(zh)
|
2016-12-02 |
2021-12-14 |
泰加生物工艺学公司 |
纳米颗粒调配物
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
SI3580561T1
(sl)
|
2017-02-12 |
2024-04-30 |
Biontech Us Inc. |
Metode, osnovane na hla, in njihove sestave ter uporabe
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
CN110832075A
(zh)
|
2017-03-22 |
2020-02-21 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
WO2018191553A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
MX2019012398A
(es)
|
2017-04-18 |
2020-09-25 |
Broad Inst Inc |
Composiciones para detectar secreciones y metodos de uso.
|
EP3638218A4
(de)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zum targeting von komplementierender komponente 3 zur hemmung des tumorwachstums
|
SG11202000612TA
(en)
|
2017-08-03 |
2020-02-27 |
Taiga Biotechnologies Inc |
Methods and compositions for the treatment of melanoma
|
US10149898B2
(en)
|
2017-08-03 |
2018-12-11 |
Taiga Biotechnologies, Inc. |
Methods and compositions for the treatment of melanoma
|
CN111511388A
(zh)
|
2017-09-21 |
2020-08-07 |
博德研究所 |
用于靶向核酸编辑的系统、方法和组合物
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
CN112292138A
(zh)
|
2018-01-22 |
2021-01-29 |
西雅图儿童医院(Dba西雅图儿童研究所) |
Car t细胞的使用方法
|
EP3762410A4
(de)
|
2018-03-06 |
2022-04-06 |
The Trustees of the University of Pennsylvania |
Prostataspezifische membran-antigen-cars und verfahren zu deren verwendung
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
US20210246503A1
(en)
|
2018-06-11 |
2021-08-12 |
The Broad Institute, Inc. |
Lineage tracing using mitochondrial genome mutations and single cell genomics
|
CN112203725A
(zh)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
Bcma嵌合抗原受体及其用途
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020068304A2
(en)
|
2018-08-20 |
2020-04-02 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
US20210355522A1
(en)
|
2018-08-20 |
2021-11-18 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease activity and uses thereof
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
EP3942023A1
(de)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Zusammensetzungen und verfahren zur modulation metabolischer regulatoren der t-zell-pathogenität
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
AR120563A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quimérico cd19 y cd22 y sus usos
|
GB201918341D0
(en)
*
|
2019-12-12 |
2020-01-29 |
Lift Biosciences Ltd |
Cells for treating infections
|
CA3188988A1
(en)
|
2020-08-13 |
2022-02-17 |
Sidi CHEN |
Compositions and methods for engineering and selection of car t cells with desired phenotypes
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|